Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications

Purpose of reviewMost epidemiologic studies have demonstrated an increased risk of cancer in scleroderma patients. Reasons for this risk increase have been poorly understood and often attributed to cytotoxic therapies or damage from scleroderma. Recognition that some patients have a close temporal relationship between cancer diagnosis and scleroderma clinical onset has focused attention on the possibility that scleroderma may be a paraneoplastic syndrome in a subset of patients. This review will discuss the latest epidemiologic data linking cancer and scleroderma and explore a model for the development of paraneoplastic scleroderma. Recent findingsNew investigations have demonstrated an association between RNA polymerase III autoantibodies and a close temporal relationship between cancer diagnosis and the development of clinical scleroderma. A unique nucleolar RNA polymerase III expression pattern has been identified in malignant tissue from these scleroderma patients suggesting that autoantigen expression in the cancer and the autoantibody response are associated. Similar data in inflammatory myositis have illustrated that disease-specific autoantigens may be expressed in cancers and damaged target tissues (muscle) undergoing regeneration. SummaryThese data suggest a model of paraneoplastic autoimmunity in which cross-reactive immune responses may target autoantigens that are expressed in both cancers and diseased autoimmune target tissues.

[1]  R. Darnell,et al.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies , 1993, The Lancet.

[2]  T. Medsger,et al.  Cancer and systemic sclerosis. An epidemiologic study. , 1985, Arthritis and rheumatism.

[3]  J. Wolchok,et al.  Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. , 2006, Advances in immunology.

[4]  David T Felson,et al.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study , 2001, The Lancet.

[5]  R. Graham,et al.  Carcinoma of breast and scleroderma: four further cases and a literature review. , 1989, British journal of rheumatology.

[6]  D. Felson,et al.  The overall and temporal association of cancer with polymyositis and dermatomyositis. , 1994, The Journal of rheumatology.

[7]  S. Levine.  Cancer and myositis: new insights into an old association , 2006, Current opinion in rheumatology.

[8]  R. Darnell,et al.  Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system , 1993, Neuron.

[9]  S. O’Day,et al.  Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. , 2006, The Journal of investigative dermatology.

[10]  Carl G. Figdor,et al.  Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients , 2008, Cancer Immunology, Immunotherapy.

[11]  G. Rodnan,et al.  Bleomycin-induced scleroderma. , 1980, The Journal of rheumatology.

[12]  J. Mclaughlin,et al.  Incidence of cancer among patients with systemic sclerosis , 1995, Cancer.

[13]  M. Comer,et al.  Remission of scleroderma during chemotherapy for lymphoma. , 1992, Annals of the rheumatic diseases.

[14]  C. Bokemeyer,et al.  Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. , 1995, European journal of cancer.

[15]  B. Sigurgeirsson,et al.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. , 1992, The New England journal of medicine.

[16]  C. Kitchens,et al.  Dermatomyositis associated with malignant melanoma. Parallel occurrence, remission, and relapse of the two processes in a patient , 1983, Cancer.

[17]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[18]  R. Winkelmann,et al.  Cancer and scleroderma. , 1979, Archives of dermatology.

[19]  RJ Buckanovich,et al.  The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  J. Peyrat,et al.  Association between systemic sclerosis and breast cancer: eight new cases and review of the literature , 2004, Clinical Rheumatology.

[21]  J. Mclaughlin,et al.  Scleroderma and malignancy: an epidemiological study. , 1993, Annals of the rheumatic diseases.

[22]  M. Rosenblum,et al.  Detection of the anti‐Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy , 1991, Neurology.

[23]  T. Mimori,et al.  Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. , 1996, Arthritis and rheumatism.

[24]  S. Jimenez,et al.  Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. , 1991, JAMA.

[25]  R. Knobler,et al.  Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma. , 2002, Clinical and experimental rheumatology.

[26]  D. Roder,et al.  Risk of cancer in patients with scleroderma: a population based cohort study , 2003, Annals of the rheumatic diseases.

[27]  J. Darnell,et al.  Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. , 2000, Cancer research.

[28]  A. Scope,et al.  Breast cancer and scleroderma. , 2006, Skinmed.

[29]  M. Rosenblum,et al.  Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. , 1990 .

[30]  Ami A. Shah,et al.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. , 2010, Arthritis and rheumatism.

[31]  J. Guilhou,et al.  Gemcitabine-associated scleroderma-like changes of the lower extremities. , 2004, Journal of the American Academy of Dermatology.

[32]  R. Evely,et al.  Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. , 2008, Rheumatology.

[33]  M. Kris,et al.  Detection of the anti‐Hu antibody in the serum of patients with small cell lung cancer—A quantitative western blot analysis , 1990, Annals of neurology.

[34]  P. Creamer,et al.  Malignancy in scleroderma patients from south west England: a population-based cohort study , 2011, Rheumatology International.

[35]  M. Hasegawa,et al.  Systemic Sclerosis Revealing T-Cell Lymphoma , 1999, Dermatology.

[36]  M. Clowse,et al.  Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. , 2003, The Journal of rheumatology.

[37]  A. Houghton,et al.  Autoimmunity and tumor immunity induced by immune responses to mutations in self , 2006, Nature Medicine.

[38]  R. Williams,et al.  Dermatomyositis and malignancy: a review of the literature. , 1959, Annals of internal medicine.

[39]  A. Mammen,et al.  Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. , 2009, Arthritis and rheumatism.

[40]  M. Hochberg,et al.  Incidence of lung cancer in systemic sclerosis. , 1985, The Journal of rheumatology.

[41]  A. Rodger,et al.  Post‐irradiation morphoea , 1989, The British journal of dermatology.

[42]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[43]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.

[44]  E. O'Keefe,et al.  Cutaneous toxicity of bleomycin therapy. , 1973, Archives of dermatology.

[45]  L. Gergely,et al.  Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis , 2008, Clinical Rheumatology.

[46]  A. Ceribelli,et al.  Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies , 2011, The Journal of Rheumatology.

[47]  R. Winkelmann,et al.  Gynecologic Carcinoma Associated With Dermatomyositis–Polymyositis , 1984, Obstetrics and gynecology.

[48]  P. Fishman,et al.  Autoantibodies to tyrosinase , 1997, Cancer.

[49]  F. Guillemin,et al.  Cancer in systemic sclerosis. , 1993, Arthritis and rheumatism.

[50]  R. Darnell,et al.  Paraneoplastic syndromes involving the nervous system. , 2003, The New England journal of medicine.

[51]  H. Sørensen,et al.  Systemic sclerosis and the risk of cancer: a nationwide population‐based cohort study , 2010, The British journal of dermatology.

[52]  S. Jimenez,et al.  A cohort study of cancer incidence in systemic sclerosis. , 2006, The Journal of rheumatology.

[53]  J. Dalmau,et al.  Selective expression of Purkinje‐cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration , 1991, The New England journal of medicine.

[54]  A. Kopf,et al.  Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.

[55]  G. Giles,et al.  Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study , 2001, Annals of Internal Medicine.

[56]  P. Quaglino,et al.  Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  E. Gabrielson,et al.  Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy , 2005, The Journal of experimental medicine.